Filing identity and period
The supplied filing is Trxade Group, Inc.’s unaudited Form 10-Q for the quarter and nine months ended September 30, 2016, filed November 14, 2016. This does not match the request metadata naming Scienture Holdings, Inc.; verify the issuer before relying on this summary.
Trxade operates a pharmaceutical business-to-business marketplace, Westminster sells pharmaceuticals and shifted toward private-label distribution in July 2016, and newly formed UK subsidiary ShopRX is intended to develop a similar marketplace.
Financial results and liquidity
| Metric | Q3 2016 | Q3 2015 | Nine months 2016 | Nine months 2015 |
|---|---|---|---|---|
| Revenue | $803,278 | $1,637,875 | $4,339,419 | $3,501,203 |
| Gross profit | $572,606 | $937,238 | $2,052,776 | $2,188,099 |
| Gross margin | 71.3% | 57.2% | 47.3% | 62.5% |
| Operating loss | $(791,900) | $(76,563) | $(2,115,041) | $(545,662) |
| Net loss | $(842,880) | $(123,762) | $(2,317,075) | $(621,738) |
Basic and diluted loss per share were $(0.03) for Q3 and $(0.07) for the nine-month period, versus $(0.00) and $(0.02), respectively, in 2015.
- Cash flow: Nine-month operating cash use was $1,557,073, compared with $785,980 in 2015. Financing provided $791,492, compared with $405,000. Cash fell by $765,581 to $94,551.
- Balance sheet at September 30: Current assets were $1,349,448 and current liabilities $1,840,032, resulting in negative working capital of $490,584. At December 31, 2015, working capital was positive $975,405.
- Debt: Total liabilities were $2,846,768; total debt includes short- and long-term notes, some secured by company assets. The company reported $1,200,000 principal of long-term convertible notes, before unamortized discount. Current short-term notes also carry substantial principal balances; reported carrying values are net of debt discounts.
- Equity: Shareholders’ deficit was $1,425,820, versus equity of $267,017 at year-end 2015. Shares outstanding at November 14 were 31,660,827.
Material changes and management commentary
- Nine-month revenue rose 24%, but gross profit fell 6%; net loss widened to $2.32 million from $622,000. Higher pharmaceutical sales and their associated cost of sales contributed to the revenue and cost increases.
- Q3 revenue declined about 51% year over year as Westminster discontinued its wholesale business and transitioned toward private-label distribution. Q3 net loss increased to $843,000 from $124,000.
- Management attributed higher expenses and cash use to staffing, platform and ERP development, professional fees, inventory purchases, and the ShopRX launch. ERP implementation added about $100,000 of consulting expense in Q3.
- Management estimated the next 12 months’ operating expenses and working-capital requirements at approximately $9 million: $4 million cost of sales and $5 million general and administrative expense. It said additional capital would be needed.
Outlook, risks, contingencies, and unusual items
- Going concern: The filing states recurring operating losses and working-capital needs raise substantial doubt about the company’s ability to continue as a going concern. Continued operations depend on raising capital and achieving profitable operations; neither is assured.
- Financing and dilution: The company funded operations with equity, debt, and operating revenue. Additional equity may dilute shareholders; borrowing would increase liabilities and cash commitments. October 2016 subsequent events included $200,000 of secured convertible notes and a separate $47,000 loan.
- Debt and unusual charges: A $37,579 loss on debt extinguishment was recorded in the nine-month period. Debt discounts and warrants accompany several note issuances. In October, the company also disclosed warrants connected with a software license.
- Legal contingency: A class-action claim alleging unsolicited fax advertising was subject to a $200,000 settlement fund accrual. The filing’s notes say final approval was scheduled for February 21, 2017, while Part II says the settlement was approved by the courts in September; the status and timing are inconsistent in the filing.
- Controls and filing status: Management concluded disclosure controls and procedures were not effective. The cover page also marks “No” for having filed all required reports during the preceding 12 months; investors should verify the circumstances.
- The filing cautions that forward-looking statements are subject to risks and actual results may differ. It provides no specific revenue or profitability guidance.
Important facts to verify
- Confirm the issuer: the filing is for Trxade Group, Inc., not Scienture Holdings, Inc.
- Assess the company’s near-term liquidity, ability to raise funds, debt maturities and terms, and the going-concern warning against its $94,551 cash balance and estimated $9 million funding needs.
- Check subsequent filings for progress in Westminster’s private-label transition, ShopRX development, and the stated operating-cost plan.
- Reconcile the class-action settlement approval and the cover-page indication regarding prior SEC filing compliance.
- Review the ineffective disclosure-controls conclusion and any later remediation disclosures.